ADVENTRX Licenses Antiviral Product To Theragenex
ADVENTRX Pharmaceuticals (ANX) announced today that it had licenses its proprietary antiviral product, ANX-211, to Theragenex.
ANX-211 is an antiviral that has been shown to be effective against viruses responsible for the common cold, influenza and other maladies. ANX-211 can be applied topically or intranasally.
Theragenex, a privately held biotech company, intends on commercializing its first product based on ANX-211 during 2007.
ADVENTRX acquired the rights to ANX-211 after it had bought out SD Pharmaceuticals back in April of 2006.
Shares of ADVENTRX closed at $2.64 a share on Friday, near the 52 week low of $2.35.
_
ADVENTRX Pharmaceuticals (ANX) announced today that it had licenses its proprietary antiviral product, ANX-211, to Theragenex.
ANX-211 is an antiviral that has been shown to be effective against viruses responsible for the common cold, influenza and other maladies. ANX-211 can be applied topically or intranasally.
Theragenex, a privately held biotech company, intends on commercializing its first product based on ANX-211 during 2007.
ADVENTRX acquired the rights to ANX-211 after it had bought out SD Pharmaceuticals back in April of 2006.
Shares of ADVENTRX closed at $2.64 a share on Friday, near the 52 week low of $2.35.
_
posted by Nico at
7:36 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home